The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ANVS | -78.92% | -59.96% | -16.73% | -79% |
| S&P | +14.5% | +93.32% | +14.09% | +105% |
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aims to treat neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.
A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $42.29M | -34.3% |
| Market Cap / Employee | $5.29M | 0.0% |
| Employees | 8 | 33.3% |
| Net Income | -$6.22M | -23.9% |
| EBITDA | -$6.27M | 19.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $17.13M | 328.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -228.37% | 80.4% |
| Return On Invested Capital | 53.31% | -72.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.11M | -51.3% |
| Operating Free Cash Flow | -$5.11M | -51.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -53.96 | 9.46 | 2.28 | 1.76 | -109.30% |
| Price to Tangible Book Value | -53.96 | 9.46 | 2.28 | 1.76 | -109.30% |
| Enterprise Value to EBITDA | -20.96 | -8.74 | -0.62 | -4.01 | -49.07% |
| Return on Equity | -596.7% | -3159.1% | -280.8% | -365.0% | -19.42% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
